A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .
A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness
One hundred and eighty three patients with DSM-III-R major depressive illness were allocated r and omly to treatment with one of two new generation antidepressants , fluoxetine and lofepramine . Both patient groups had significantly lower mean scores on the Hamilton Depression Rating Scale ( HDRS ) 6 weeks after entry to the trial ( p < 0.001 ) , but there were no differences between the groups , either at baseline or after 6 weeks , in total HRDS score or in subscores for anxiety or suicidality . Anticholinergic side effects were commoner with lofepramine ; adverse effects were on the whole mild and few patients dropped out because of them . This study does not support previous cl aims of specific adverse effects of fluoxetine on anxiety and suicidality
A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .